Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/25471
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSar, Mehmet-
dc.contributor.authorÖz, Büge Turkili-
dc.contributor.authorÖner Dinçbas, Fazilet-
dc.date.accessioned2022-03-31T06:39:34Z-
dc.date.available2022-03-31T06:39:34Z-
dc.date.issued2008-01-
dc.identifier.citationEren, B. vd. (2008). "MMP-2, TIMP-2 and CD44v6 expression in non-small-cell lung carcinomas". Annals of the Academy of Medicine Singapore, 37(1), 32-39.en_US
dc.identifier.issn0304-4602-
dc.identifier.urihttps://annals.edu.sg/mmp-2-timp-2-and-cd44v6-expression-in-non-small-cell-lung-carcinomas/-
dc.identifier.urihttp://hdl.handle.net/11452/25471-
dc.description.abstractIntroduction: Factors that emerge as crucial participants in tumour invasion and metastases are matrix metalloproteinases (MMPs), tissue inhibitor of metalloproteinase (TIMP) inhibitors and cellular adhesion molecules (CD44 and similar molecules). They play important roles in tumour invasion and metastasis in non-small-cell lung carcinomas (NSCLCs). Materials and Methods: The study was performed using the data of 33 patients. MMP-2 from the metalloproteinase family, TIMP-2 from the metalloproteinase inhibitor family and the adhesion molecule CD44v6 expression were investigated immunohistochemically to search their role in the metastasis and the clinical outcome of the patients with NSCLCs. Results: Twenty-three tumours (70%) were squamous cell carcinoma (SCC), 9 (27%) were adenocarcinoma (AC), and 1 (3%) was large cell carcinoma (LCC). MMP-2 and TIMP-2 were expressed in high rates in NSCLC but CD44v6 expression was about 50%. Lymphatic invasion was less frequent in TIMP-2-positive patients and this difference was statistically significant (P = 0.005). There was a statistically significant difference between SCCs and ACs with respect to CD44v6 tumoral expression (P = 0.004). Also, there was a negative correlation between lymphatic invasion and the extent of CD44v6; lymphatic invasion was significantly less in CD446-positive cases (P = 0.013). Conclusion: We found that TIMP-2 and CD44v6 can decrease the lymphatic invasion in NSCLCs. Also there was observed histiotype-related pattern of CD44v6 variant expression in SCCs.en_US
dc.language.isoenen_US
dc.publisherAcademy of Medicine Singaporeen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAtıf Gayri Ticari Türetilemez 4.0 Uluslararasıtr_TR
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectGeneral & internal medicineen_US
dc.subjectImmunohistochemistryen_US
dc.subjectMetastasisen_US
dc.subjectPulmonary neoplasmsen_US
dc.subjectV6 spliced varianten_US
dc.subjectMatrix metalloproteinase-2en_US
dc.subjectMatrix-metalloproteinase-9en_US
dc.subjectCanceren_US
dc.subjectOverexpressionen_US
dc.subjectInhibitorsen_US
dc.subjectIsoformsen_US
dc.subjectTumorsen_US
dc.subjectLevelen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 and overen_US
dc.subject.meshAntigens, cd44en_US
dc.subject.meshCarcinomaen_US
dc.subject.meshNon-small-cell lungen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunohistochemistryen_US
dc.subject.meshMaleen_US
dc.subject.meshMatrix metalloproteinase 2en_US
dc.subject.meshMiddle ageden_US
dc.subject.meshTissue inhibitor of metalloproteinase-2en_US
dc.subject.meshTumor markers, biologicalen_US
dc.titleMMP-2, TIMP-2 and CD44v6 expression in non-small-cell lung carcinomasen_US
dc.typeArticleen_US
dc.identifier.wos000254672300007tr_TR
dc.identifier.scopus2-s2.0-41149106046tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Adli Tıp Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0002-8296-5484tr_TR
dc.identifier.startpage32tr_TR
dc.identifier.endpage39tr_TR
dc.identifier.volume37tr_TR
dc.identifier.issue1tr_TR
dc.relation.journalAnnals of the Academy of Medicine Singaporeen_US
dc.contributor.buuauthorEren, Bülent-
dc.contributor.researcheridAAK-8096-2021tr_TR
dc.relation.collaborationYurt içitr_TR
dc.identifier.pubmed18265895tr_TR
dc.subject.wosMedicine, general & internalen_US
dc.indexed.wosSCIEen_US
dc.indexed.scopusScopusen_US
dc.indexed.pubmedPubMeden_US
dc.wos.quartileQ3en_US
dc.contributor.scopusid8725969000tr_TR
dc.subject.scopusTissue Inhibitor of Metalloproteinase-1; Gelatinase A; Matrix Metalloproteinase Inhibitorsen_US
dc.subject.emtreeCd44v6 antigenen_US
dc.subject.emtreeGelatinase Aen_US
dc.subject.emtreeMetalloproteinase inhibitoren_US
dc.subject.emtreeTissue inhibitor of metalloproteinase 2en_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeClinical articleen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeImmunohistochemistryen_US
dc.subject.emtreeLung non small cell canceren_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeProtein expressionen_US
dc.subject.emtreeSquamous cell carcinomaen_US
Appears in Collections:PubMed
Scopus
Web of Science

Files in This Item:
File Description SizeFormat 
Eren_vd_2008.pdf123.61 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons